NCT05388461

Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy

Name: Clinical Trial NCT05388461
Creator: Haukeland University Hospital
Keywords: Depressive Disorder, electroconvulsive therapy, other, clinical trial, Norway

Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy for Severe or Treatment Resistant Depression - Predictors of Response, Side Effects, and Relapse

Haukeland University Hospital·ClinicalTrials.gov·otherRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Depressive Disorder
Drug/Device/Intervention: electroconvulsive therapy
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: Haukeland University Hospital
Location: Bergen,Stavanger, Norway

Timeline & enrollment

Phase: N/A
Start date: Mar 13, 2013
End date: Dec 01, 2028
Enrollment: 600 participants

Primary outcome

Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at posttreatment,Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at posttreatment,Change of Beck depression inventory (BDI) score from pretreatment at posttreatment,Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at posttreatment

Summary

The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.

ICD-10 classifications

Depressive conduct disorderRecurrent depressive disorder, unspecifiedRecurrent depressive disorderOther recurrent depressive disordersRecurrent depressive disorder, currently in remission

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05388461
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05388461 through Pure Global AI's free database. This phase not specified trial is sponsored by Haukeland University Hospital and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.